MedPiper Technologies vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 38)
MedPiper Technologies logo

MedPiper Technologies

EmergingHealthcare

General

Bengaluru Diagnostics-as-a-Service API connecting 10,000+ India labs for telehealth and insurers; YC W20 $3.28M at 91% YoY growth enabling digital health platforms to embed diagnostics without logistics.

AI VisibilityBeta
Overall Score
D38
Category Rank
#468 of 596
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
35
Perplexity
34
Gemini
41

About

MedPiper Technologies is a Bengaluru-based Diagnostics-as-a-Service (DaaS) platform — India's first comprehensive diagnostic infrastructure API — enabling insurers, health plans, telehealth providers, and healthcare organizations to embed diagnostic services (lab tests, radiology, home sample collection) into their digital health workflows through a single white-label integration. Founded in 2020 and backed by Y Combinator (W20) with $3.28 million raised, MedPiper generates ₹5.57 crore (approximately $670,000 USD) in annual revenue with 91% year-over-year growth, serving the digital health ecosystem as the infrastructure layer that connects healthcare platforms to India's fragmented diagnostic laboratory network.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

38
Overall Score
90
#468
Category Rank
#2
79
AI Consensus
83
stable
Trend
stable
35
ChatGPT
92
34
Perplexity
93
41
Gemini
89
40
Claude
96
34
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.